Please login to the form below

Not currently logged in
Email:
Password:

GLP-1 agonists

This page shows the latest GLP-1 agonists news and features for those working in and with pharma, biotech and healthcare.

Novo's semaglutide beats Lilly's Trulicity in diabetes contest

Novo's semaglutide beats Lilly's Trulicity in diabetes contest

Novo Nordisk says its once-weekly GLP-1 agonist semaglutide could become a "new standard" in type 2 diabetes after beating rival Eli Lilly's Trulicity (dulaglutide) in a phase III ... Trulicity's growth stems from its once-weekly dosing, which has proved

Latest news

  • Sanofi's lixisenatide is back under FDA review Sanofi's lixisenatide is back under FDA review

    Sanofi's lixisenatide is back under FDA review. Brings GLP-1 agonist closer to US market. ... Meanwhile, new GLP-1 agonists that require dosing just once a week - including Eli Lilly's Trulicity (dulaglutide), GlaxoSmithKline's Tanzeum (albiglutide)

  • Sanofi plans LixiLan filings after positive phase III trial Sanofi plans LixiLan filings after positive phase III trial

    Jefferies' Peter Wellford indicating earlier this year that the basal insulin/GLP-1 agonists could herald a 'paradigm shift' in the treatment of type 2 diabetes. ... Sanofi's product featuring the world's biggest-selling basal insulin while Novo

  • Novo Nordisk's Victoza fails type 1 diabetes trial Novo Nordisk's Victoza fails type 1 diabetes trial

    The year-long trial involved almost 1, 400 patients who were given one of three doses of long-acting GLP-1 agonist liraglutide or placebo, given once-daily by subcutaneous injection - ... episodes. The concept of combining insulin with GLP-1 agonists has

  • Type 2 diabetes market set to hit $39bn by 2021 Type 2 diabetes market set to hit $39bn by 2021

    In particular its new report points to three classes of drugs: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium– glucose cotransporter 2 inhibitors. ... Newer versions of glucagon-like peptide-1

  • Receptos rejected AZ takeover bid, say sources Receptos rejected AZ takeover bid, say sources

    Receptos' main asset is oxanimod (RPC1063), a sphingosine 1-phosphate 1 receptor (S1P1R) modulator in phase III testing for multiple sclerosis and phase II for Crohn's disease. ... small-molecule agonists of glucagon-like peptide-1 (GLP-1), which could

More from news
Approximately 8 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142. Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics